Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Income from Continuing Operations (2016 - 2026)

Intellia Therapeutics has reported Income from Continuing Operations over the past 12 years, most recently at 95327000.0 for Q1 2026.

  • Quarterly Income from Continuing Operations rose 15.04% to 95327000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 394918000.0 through Mar 2026, up 20.59% year-over-year, with the annual reading at 411795000.0 for FY2025, 15.35% up from the prior year.
  • Income from Continuing Operations was 95327000.0 for Q1 2026 at Intellia Therapeutics, down from 92234000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 92234000.0 in Q4 2025 and troughed at 143706000.0 in Q1 2022.
  • The 5-year median for Income from Continuing Operations is 104763000.0 (2025), against an average of 112274058.82.
  • Year-over-year, Income from Continuing Operations tumbled 211.02% in 2022 and then surged 30.43% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 104733000.0 in 2022, then fell by 21.67% to 127433000.0 in 2023, then rose by 1.27% to 125816000.0 in 2024, then grew by 26.69% to 92234000.0 in 2025, then dropped by 3.35% to 95327000.0 in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Income from Continuing Operations are 95327000.0 (Q1 2026), 92234000.0 (Q4 2025), and 104763000.0 (Q3 2025).